Compare SMTC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTC | ALKS |
|---|---|---|
| Founded | 1960 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.7B |
| IPO Year | 2002 | 2012 |
| Metric | SMTC | ALKS |
|---|---|---|
| Price | $125.88 | $51.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $93.20 | $43.43 |
| AVG Volume (30 Days) | ★ 3.5M | 2.3M |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.65 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | $1,049,975,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $20.10 | $24.26 |
| Revenue Next Year | $13.01 | $4.47 |
| P/E Ratio | $466.85 | ★ N/A |
| Revenue Growth | ★ 15.47 | N/A |
| 52 Week Low | $46.02 | $25.17 |
| 52 Week High | $177.35 | $55.67 |
| Indicator | SMTC | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 59.89 |
| Support Level | $122.89 | $27.78 |
| Resistance Level | $174.91 | $55.67 |
| Average True Range (ATR) | 9.40 | 1.70 |
| MACD | -2.05 | -0.62 |
| Stochastic Oscillator | 24.01 | 30.95 |
Semtech Corp is a provider of high-performance semiconductors powering data center networking, Internet of Things ("IoT") connectivity, and cellular infrastructure solutions. The company designs, develops, manufactures, and markets a diverse portfolio of products for commercial applications, addressing the infrastructure, high-end consumer, and industrial end markets. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems, and Connected Services. The majority of the company's revenue is earned through the Analog Mixed Signal and Wireless segment. Geographically, the majority of the company's revenue is earned from the Asia Pacific region; the company also operates in North America and Europe.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.